Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer
This early-stage study tests a new combination treatment using a special immune-boosting vaccine and a hormone-blocking medication called elacestrant. Researchers want to see if this approach is safe and feasible for treating advanced breast cancer.
You might be eligible if you have hormone-positive, HER2-negative breast cancer that has spread, and genetic testing shows a specific change called an ESR1 mutation. You must have also tried previous hormone therapies and a CDK 4/6 inhibitor drug.
Participants will receive the study treatments, which include the elacestrant medication and specialized vaccines, while doctors carefully monitor your health and safety. You will also have regular check-ins and medical tests to see how your body responds to the treatment.
This study currently takes place in Tampa, Florida, and is active but not currently looking for new participants.
- 1Tests a combination of an immune vaccine and a hormone-blocking drug.
- 2Specifically for advanced breast cancer with a certain gene change.
- 3Currently active in Tampa, Florida, but not recruiting new patients.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.